A Review of Olmesartan-based Therapy in Targeting Effective Blood Pressure Control and Achieving Blood Pressure Goals

J Assoc Physicians India. 2024 Mar;72(3):75-78. doi: 10.59556/japi.72.0480.

Abstract

For >3 decades now, angiotensin receptor blockers (ARB) have been used in the management of hypertension (HTN) and HTN-related cardiovascular (CV) diseases. Olmesartan medoxomil (OLM) is an angiotensin II type 1 (AT1) receptor antagonist (or blocker) that binds tightly to the AT1 receptor with long-lasting efficacy over the 24-hour period and safety demonstrated in several trials. It is well tolerated and effective in reducing blood pressure (BP) in mono and combination therapy with thiazide diuretics or calcium channel blockers across a wide range of patient subgroups. The effectiveness and safety of OLM-based combination therapies have good and tolerable profiles with high adherence in the fixed single-pill formulation. Consistent antihypertensive efficacy and good tolerability when used as monotherapy or as a combined therapy make OLM a valuable treatment option for adults with HTN. In this review, we discuss the important clinical implications of OLM as an optimal choice as monotherapy and combination therapy in managing patients with HTN.

Publication types

  • Review

MeSH terms

  • Angiotensin II Type 1 Receptor Blockers* / therapeutic use
  • Antihypertensive Agents* / therapeutic use
  • Blood Pressure* / drug effects
  • Drug Therapy, Combination*
  • Humans
  • Hypertension* / drug therapy
  • Imidazoles* / therapeutic use
  • Olmesartan Medoxomil / therapeutic use
  • Tetrazoles / therapeutic use

Substances

  • Antihypertensive Agents
  • Angiotensin II Type 1 Receptor Blockers
  • Imidazoles
  • Tetrazoles
  • Olmesartan Medoxomil
  • olmesartan